AR018183A1 - Formulacion terapeutica en aerosol que comprende un agente terapeutico en la forma de particulas recubiertas por lo menos por un excipiente derecubrimiento y por lo menos un surfactante, en suspension en un gas propelente licuado para la administracion de agentes terapeuticos particularmentepor la r - Google Patents
Formulacion terapeutica en aerosol que comprende un agente terapeutico en la forma de particulas recubiertas por lo menos por un excipiente derecubrimiento y por lo menos un surfactante, en suspension en un gas propelente licuado para la administracion de agentes terapeuticos particularmentepor la rInfo
- Publication number
- AR018183A1 AR018183A1 ARP990101747A ARP990101747A AR018183A1 AR 018183 A1 AR018183 A1 AR 018183A1 AR P990101747 A ARP990101747 A AR P990101747A AR P990101747 A ARP990101747 A AR P990101747A AR 018183 A1 AR018183 A1 AR 018183A1
- Authority
- AR
- Argentina
- Prior art keywords
- formulations
- suspension
- drug
- propellant
- administration
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 8
- 238000009472 formulation Methods 0.000 title abstract 7
- 239000000203 mixture Substances 0.000 title abstract 7
- 239000002245 particle Substances 0.000 title abstract 5
- 239000000725 suspension Substances 0.000 title abstract 4
- 229940124597 therapeutic agent Drugs 0.000 title abstract 3
- 239000004094 surface-active agent Substances 0.000 title abstract 2
- 239000000443 aerosol Substances 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000003380 propellant Substances 0.000 abstract 6
- 229940079593 drug Drugs 0.000 abstract 5
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- 239000011248 coating agent Substances 0.000 abstract 2
- 238000000576 coating method Methods 0.000 abstract 2
- 210000002345 respiratory system Anatomy 0.000 abstract 2
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 abstract 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 abstract 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 abstract 1
- 229950000210 beclometasone dipropionate Drugs 0.000 abstract 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008249 pharmaceutical aerosol Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 229960005018 salmeterol xinafoate Drugs 0.000 abstract 1
- 230000007928 solubilization Effects 0.000 abstract 1
- 238000005063 solubilization Methods 0.000 abstract 1
- 238000009736 wetting Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
El reemplazo de propelentes de clorofluorcarbono con propelentes que protegen la capa de ozono tienen problemas asociados con la estabilidad de lasuspension debido a la solubilidad parcial de la droga en el gas, resultando en un tamano incrementado,formacion de agregados que puede bloquear lasválvulas del dispositivo de administracion y/o en una forma menos buena en las vías respiratorias inferiores. En contraste, presentamos lasformulaciones farmacéuticas en aerosol que comprenden: (A) un agente terapéutico (preferiblemente dipropionato de beclometasona o xinafoato de salmeterol)en la forma de partículas recubiertas por lo menos con un excipiente de recubrimiento y por lo menos un surfactante, en suspension en (B) un gaspropelente licuado para la administracion de agentes terapéuticos particularmente por la ruta pulmonar y un proceso para la preparacion de estasformulaciones. También se relaciona con partículas micronizadas adecuadas para uso en tales formulaciones. Tales formulaciones tienen una estabilidadde las drogas en suspension mejorada en el propelente por medio de la proteccion de las partículas de droga del propelente con un recubrimiento, previniendola solubilizacion parcial de la droga en el propelente y la formacion de agregados. Además, las formulaciones son estables en ausencia de humedadatmosférica durante meses y permite la administracion de la droga en las vías respiratorios. Se describen también partículas y cartuchos conteniendolas formulaciones.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9808152.4A GB9808152D0 (en) | 1998-04-18 | 1998-04-18 | Pharmaceutical aerosol formulation |
| GBGB9814709.3A GB9814709D0 (en) | 1998-07-08 | 1998-07-08 | Pharmaceutical aerosol formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR018183A1 true AR018183A1 (es) | 2001-10-31 |
Family
ID=26313483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990101747A AR018183A1 (es) | 1998-04-18 | 1999-04-15 | Formulacion terapeutica en aerosol que comprende un agente terapeutico en la forma de particulas recubiertas por lo menos por un excipiente derecubrimiento y por lo menos un surfactante, en suspension en un gas propelente licuado para la administracion de agentes terapeuticos particularmentepor la r |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US7521042B2 (es) |
| EP (1) | EP1073417B1 (es) |
| JP (1) | JP2002512183A (es) |
| KR (1) | KR20010042816A (es) |
| CN (1) | CN1145478C (es) |
| AP (1) | AP2000001961A0 (es) |
| AR (1) | AR018183A1 (es) |
| AT (1) | ATE228823T1 (es) |
| AU (1) | AU755066B2 (es) |
| BR (1) | BR9909736A (es) |
| CA (1) | CA2328882A1 (es) |
| CO (1) | CO5021210A1 (es) |
| DE (1) | DE69904312T2 (es) |
| DK (1) | DK1073417T3 (es) |
| EA (1) | EA200000956A1 (es) |
| EE (1) | EE200000608A (es) |
| ES (1) | ES2189410T3 (es) |
| HR (1) | HRP20000689A2 (es) |
| HU (1) | HUP0101608A2 (es) |
| ID (1) | ID27887A (es) |
| IL (1) | IL139087A0 (es) |
| IS (1) | IS5665A (es) |
| MA (1) | MA26621A1 (es) |
| NO (1) | NO20005218L (es) |
| NZ (1) | NZ507619A (es) |
| PE (1) | PE20000433A1 (es) |
| PL (1) | PL343491A1 (es) |
| PT (1) | PT1073417E (es) |
| TR (1) | TR200100144T2 (es) |
| WO (1) | WO1999053901A1 (es) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9616237D0 (en) | 1996-08-01 | 1996-09-11 | Norton Healthcare Ltd | Aerosol formulations |
| US6119853A (en) * | 1998-12-18 | 2000-09-19 | Glaxo Wellcome Inc. | Method and package for storing a pressurized container containing a drug |
| US6390291B1 (en) * | 1998-12-18 | 2002-05-21 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
| ES2193069T3 (es) | 1999-04-14 | 2003-11-01 | Glaxo Group Ltd | Formulacion farmaceutica en aerosol. |
| PT2283817T (pt) † | 2000-11-30 | 2016-08-22 | Vectura Ltd | Método de fabrico de partículas para utilização numa composição farmacêutica |
| US7560160B2 (en) | 2002-11-25 | 2009-07-14 | Materials Modification, Inc. | Multifunctional particulate material, fluid, and composition |
| KR20100107083A (ko) * | 2002-12-17 | 2010-10-04 | 메디뮨 엘엘씨 | 생물활성 물질의 고압 분무 건조 |
| ITMI20022674A1 (it) * | 2002-12-18 | 2004-06-19 | Chiesi Farma Spa | Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione. |
| US20040121003A1 (en) * | 2002-12-19 | 2004-06-24 | Acusphere, Inc. | Methods for making pharmaceutical formulations comprising deagglomerated microparticles |
| US6962006B2 (en) * | 2002-12-19 | 2005-11-08 | Acusphere, Inc. | Methods and apparatus for making particles using spray dryer and in-line jet mill |
| PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| CN1791386A (zh) * | 2003-05-19 | 2006-06-21 | 巴克斯特国际公司 | 抗癫痫和抗痴呆药物以及免疫抑制剂的小－颗粒药物制剂 |
| US7448389B1 (en) | 2003-10-10 | 2008-11-11 | Materials Modification, Inc. | Method and kit for inducing hypoxia in tumors through the use of a magnetic fluid |
| TWI341836B (en) | 2004-03-11 | 2011-05-11 | Theravance Inc | Biphenyl compounds useful as muscarinic receptor antagonists |
| WO2006023460A2 (en) | 2004-08-16 | 2006-03-02 | Theravance, Inc. | COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY |
| RU2007133547A (ru) * | 2005-02-10 | 2009-03-20 | Глаксо Груп Лимитед (GB) | Способы получения лактозы с использованием методов предварительной сортировки и приготовляемые из нее фармацевтические композиции |
| WO2008000042A1 (en) | 2006-06-30 | 2008-01-03 | Iceutica Pty Ltd | Methods for the preparation of biologically active compounds in nanoparticulate form |
| US20080276935A1 (en) | 2006-11-20 | 2008-11-13 | Lixiao Wang | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
| US8414525B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
| US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US8414526B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids |
| US8414910B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US8425459B2 (en) * | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
| US8998846B2 (en) | 2006-11-20 | 2015-04-07 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
| US20080175887A1 (en) | 2006-11-20 | 2008-07-24 | Lixiao Wang | Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs |
| WO2010024898A2 (en) | 2008-08-29 | 2010-03-04 | Lutonix, Inc. | Methods and apparatuses for coating balloon catheters |
| EP3620154A1 (en) | 2009-02-06 | 2020-03-11 | University Of Southern California | Therapeutic compositions comprising monoterpenes |
| JP5809985B2 (ja) | 2009-02-26 | 2015-11-11 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | ４−｛（１ｒ）−２−［（６−｛２−［（２，６−ジクロロベンジル）オキシ］エトキシ｝ヘキシル）アミノ］−１−ヒドロキシエチル｝−２−（ヒドロキシメチル）フェノールを含む医薬製剤 |
| SI2453894T1 (sl) | 2009-07-15 | 2016-02-29 | Theravance Biopharma R&D Ip, Llc | Kristalinična oblika proste baze bifenilne spojine |
| GB0921075D0 (en) | 2009-12-01 | 2010-01-13 | Glaxo Group Ltd | Novel combination of the therapeutic agents |
| CA2828833C (en) | 2010-03-03 | 2020-11-03 | Neonc Technologies Inc. | Pharmaceutical compositions comprising monoterpenes |
| WO2011155451A1 (ja) | 2010-06-08 | 2011-12-15 | 学校法人神戸学院 | コーティング粒子及びコーティング粒子の製造方法 |
| WO2012083178A1 (en) | 2010-12-17 | 2012-06-21 | Neo Oncology Inc. | Methods and devices for using isoperillyl alcohol |
| US20160038600A1 (en) | 2012-08-03 | 2016-02-11 | Neonc Technologies Inc. | Pharmaceutical compositions comprising poh derivatives |
| ES2600928T3 (es) | 2010-08-27 | 2017-02-13 | Neonc Technologies Inc. | Composiciones farmacéuticas que comprenden derivados de alcohol perilílico |
| CN102366405A (zh) * | 2011-10-21 | 2012-03-07 | 江阴长风医药科技有限公司 | 以氢氟烷烃为抛射剂的氟替卡松丙酸酯气雾剂制剂 |
| WO2013128283A2 (en) | 2012-02-28 | 2013-09-06 | Iceutica Holdings Inc. Bvi | Inhalable pharmaceutical compositions |
| SI2968313T1 (en) | 2013-03-15 | 2018-05-31 | Verona Pharma Plc | Combination of medicines |
| PL3231444T3 (pl) | 2014-05-12 | 2020-05-18 | Verona Pharma Plc | Nowe leczenie |
| EP3872069A1 (en) | 2015-02-12 | 2021-09-01 | Neonc Technologies, Inc. | Pharmaceutical compositions comprising perillyl alcohol derivatives |
| CN106546751A (zh) * | 2016-11-16 | 2017-03-29 | 广州华弘生物科技有限公司 | 用于检测oct4蛋白的酶联免疫试剂盒 |
| CN110267538B (zh) | 2016-11-30 | 2022-04-19 | 尼昂克技术公司 | 紫苏醇-3-溴丙酮酸缀合物和治疗癌症的方法 |
| BR112020016074A2 (pt) | 2018-02-08 | 2020-12-08 | Neonc Technologies, Inc | Métodos de permeabilização da barreira hematoencefálica |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5141674A (en) * | 1984-03-08 | 1992-08-25 | Phares Pharmaceutical Research N.V. | Methods of preparing pro-liposome dispersions and aerosols |
| PT85521B (pt) * | 1986-08-11 | 1990-06-29 | Innovata Biomed Ltd | Processo para a preparacao de composicoes farmaceuticas que consistem em microcapsulas |
| GB9024365D0 (en) * | 1990-11-09 | 1991-01-02 | Glaxo Group Ltd | Medicaments |
| EP0655237A1 (de) * | 1993-11-27 | 1995-05-31 | Hoechst Aktiengesellschaft | Medizinische Aerosolformulierung |
| GB9426252D0 (en) * | 1994-12-24 | 1995-02-22 | Glaxo Group Ltd | Pharmaceutical composition |
| EP0834314B1 (en) * | 1995-06-12 | 2003-01-15 | Ono Pharmaceutical Co., Ltd. | Granules containing pranlukast, process for producing the granules, and method of lowering cohesiveness of pranlukast |
| GB9606677D0 (en) * | 1996-03-29 | 1996-06-05 | Glaxo Wellcome Inc | Process and device |
| AU5806998A (en) * | 1996-12-31 | 1998-07-31 | Inhale Therapeutic Systems | Processes for spray drying solutions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes |
-
1999
- 1999-04-15 DK DK99916921T patent/DK1073417T3/da active
- 1999-04-15 AT AT99916921T patent/ATE228823T1/de not_active IP Right Cessation
- 1999-04-15 CA CA002328882A patent/CA2328882A1/en not_active Abandoned
- 1999-04-15 ID IDW20002392A patent/ID27887A/id unknown
- 1999-04-15 PL PL99343491A patent/PL343491A1/xx unknown
- 1999-04-15 ES ES99916921T patent/ES2189410T3/es not_active Expired - Lifetime
- 1999-04-15 WO PCT/EP1999/002535 patent/WO1999053901A1/en not_active Ceased
- 1999-04-15 DE DE69904312T patent/DE69904312T2/de not_active Expired - Fee Related
- 1999-04-15 JP JP2000544308A patent/JP2002512183A/ja not_active Ceased
- 1999-04-15 EP EP99916921A patent/EP1073417B1/en not_active Expired - Lifetime
- 1999-04-15 AR ARP990101747A patent/AR018183A1/es unknown
- 1999-04-15 KR KR1020007011572A patent/KR20010042816A/ko not_active Withdrawn
- 1999-04-15 AU AU35231/99A patent/AU755066B2/en not_active Ceased
- 1999-04-15 CO CO99022532A patent/CO5021210A1/es unknown
- 1999-04-15 HU HU0101608A patent/HUP0101608A2/hu unknown
- 1999-04-15 MA MA25536A patent/MA26621A1/fr unknown
- 1999-04-15 AP APAP/P/2000/001961A patent/AP2000001961A0/en unknown
- 1999-04-15 EE EEP200000608A patent/EE200000608A/xx unknown
- 1999-04-15 IL IL13908799A patent/IL139087A0/xx unknown
- 1999-04-15 EA EA200000956A patent/EA200000956A1/ru unknown
- 1999-04-15 BR BR9909736-2A patent/BR9909736A/pt not_active Application Discontinuation
- 1999-04-15 HR HR20000689A patent/HRP20000689A2/hr not_active Application Discontinuation
- 1999-04-15 TR TR2001/00144T patent/TR200100144T2/xx unknown
- 1999-04-15 CN CNB998072818A patent/CN1145478C/zh not_active Expired - Fee Related
- 1999-04-15 PT PT99916921T patent/PT1073417E/pt unknown
- 1999-04-15 NZ NZ507619A patent/NZ507619A/en unknown
- 1999-04-16 PE PE1999000318A patent/PE20000433A1/es not_active Application Discontinuation
-
2000
- 2000-10-13 IS IS5665A patent/IS5665A/is unknown
- 2000-10-17 NO NO20005218A patent/NO20005218L/no not_active Application Discontinuation
-
2003
- 2003-02-11 US US10/364,257 patent/US7521042B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2077971T5 (es) | Formulaciones medicinales en aerosol que comprenden salbutamol. | |
| ES2158911T5 (es) | Formulaciones en aerosol sin clorofluorocarbonos. | |
| ES2238334T3 (es) | Formulacion farmaceutica en aerosol de salmeterol y propionato de fluticasona. | |
| ES2244008T3 (es) | Composiciones farmaceuticas y dispositivos para su administracion. | |
| ES2320194T3 (es) | Formulaciones en solucion farmaceutica estables para inhaladores presurizados de dosis medidas. | |
| ES2343045T3 (es) | Una formulacion medicinal en aerosol. | |
| ES2292713T3 (es) | Formulaciones medicinales en aerosol. | |
| ES2217277T3 (es) | Aerosoles medicos que contienen propelente hidrofluorocarbonado. | |
| ES2255767T3 (es) | Inhaladores presurizados de dosis medida. | |
| US6461591B1 (en) | Medical aerosol formulations | |
| ES2211108T3 (es) | Formulaciones farmaceuticas para aerosoles con dos o mas sustancias activas. | |
| ES2274803T3 (es) | Formulacion farmaceutica de propionato de fluticasona. | |
| JP2003518484A5 (es) | ||
| JPH10510521A (ja) | エアゾール処方物用噴射剤混合物 | |
| MX9207205A (es) | Formulacion farmaceutica en aerosol, bote para suministrarar dicha formulacion e inhalador de dosis dosificada que comprende dicho bote. | |
| KR920017643A (ko) | 약제학적 에어로졸 제제 | |
| HU226694B1 (en) | Medicinal aerosol products containing ciclesonide | |
| EP0602181A1 (en) | Medicinal aerosol formulations | |
| EP1458357B1 (en) | Medicinal aerosol compositions with a functionalized polyethyleneglycol excipient | |
| US20130104881A1 (en) | Stabilized Metered Dose Inhaler | |
| ES2259915B1 (es) | Nueva formulacion estable de aerosoles en suspension y procedimiento de obtencion. | |
| ES2317306T3 (es) | Procedimiento para la preparacion de formulaciones en aerosol en suspension, en el que las particulas se forman por precipitacion dentro de un frasco de aerosol. | |
| ES2230066T3 (es) | Aerosoles dosificadores con isobutano como propelente. | |
| KR20060106823A (ko) | 약제학적 에어로졸 조성물 | |
| ES2314469T3 (es) | Formulacion farmaceutica en aerosol que comprende un hidrofluoroalcano y una ciclodextrina acilada. |